IRVINE, Calif.--Functional genomics firm Reprogen named biophysicist and attorney Jeffrey Miller to the post of president and CEO. In previous positions as senior vice-president, corporate development, at Ostex Interna tion al for one year and at NeoRx for nine years, Miller negotiated strategic alliances with leading pharmaceuticals.
Reprogen also completed $5.1 million in private financing in February. Investors included UBS, Canadian venture fund Genechem, and current investors, Oxford Investors and BIMV, a Belgian venture fund. Reprogen uses functional genomics to identify molecular targets involved in reproductive diseases including endometriosis and ovarian, breast, and prostate cancers.